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Abstract 
Treatment of pityriasis rubra pilaris is still challenging. We here present a 74-year-old 
woman who had not experienced stable remission of her skin symptoms during prior 
treatments including topical and systemic corticosteroids, phototherapy, orally 
administered acitretin, cyclosporine, methotrexate and adalimumab. A therapy with oral 
alitretinoin was started and tolerated very well. After a few weeks, skin condition 
improved significantly and itching and scaling disappeared. The present case shows that 
alitretinoin might be an alternative in the treatment of recalcitrant pityriasis rubra pilaris 
type I. Further studies are needed to investigate the benefit of this encouraging result. 
Case Report 
We present a 74-year-old woman with a 3-year history of adult-onset pityriasis rubra pilaris (PRP) 
type I, who had not experienced stable remission of her skin symptoms during prior treatment courses. 
A skin biopsy had confirmed the diagnosis of PRP mainly affecting her palms, back, legs and soles with 
persistent, itching erythema, erythematosquamous plaques and scaling, with well-demarked areas of 
unaffected skin (‘nappes claires’) (fig. 1). Arterial hypertonus, esophageal reflux, mild 
hypercholesterolemia and triglyceridemia were reported as preexisting conditions. There was no family 
history of PRP. 
Previous treatments included topical and systemic corticosteroids (prednisone 10 mg daily for 18 
months), external capsaicin ointment, phototherapy (bath PUVA [bath of psoralen plus ultraviolet 
(UV) A rays] and orally administered acitretin (maximum dose 20 mg daily for 20 months) with no 
stable response. Oral cyclosporine had been discharged because of a worsening of arterial hypertension, 
also oral methotrexate showed no significant effect. A rescue therapy with adalimumab (Humira, 40 
mg s.c. every two weeks) had first a good response, but had then to be interrupted because of 
gastrointestinal side effects and relapse of PRP (table 1). 
In April 2010, a therapeutic regimen with oral systemic alitretinoin 30 mg daily was started and very 
well tolerated. Bland emollients and initially topical corticosteroids were used. The skin condition of our 
patient improved significantly within weeks and also the itching and scaling disappeared (fig. 2).  
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Treatment with oral alitretinoin 30 mg has been ongoing since 7 months now. No rising of serum 
cholesterol or triglyceride levels have been recognized. However, hair loss has progressed significantly 
under therapy with alitretinoin, and the patient had to be provided with a wig. Despite this invasive 
cosmetic effect related to the medication, the benefits of the therapy outweigh and a continuation of the 
therapy has been requested by the patient. 
Discussion 
PRP is a rare and severe inflammatory papulosquamous chronic dermatosis of 
unknown etiology, characterized by its resistance to therapy [1]. In generalized PRP type I 
with extensive disease symptoms, a systemic treatment is necessary in nearly all cases. In 
general, oral retinoids are used as a first-line treatment with or without UV light. Some 
effectiveness is documented for etretinate, acitretin and isotretinoin [1]. Systemic 
retinoids are of special benefit for PRP because of their anti-proliferative, 
immunomodulating and anti-inflammatory effect mediated by binding to nuclear 
receptors. 
In contrast to the above-mentioned retinoids, alitretinoin (9-cis retinoic acid) 
functions as a pan-agonist of both known nuclear retinoid receptor families (retinoic acid 
receptor RAR and retinoid X receptor RXR). Due to its expanded interaction with 
retinoid receptors, it may be more effective in so-called retinoid-responsive dermatoses 
with less side effects. It has been reported that vitamin A enhances Th2 development in 
vitro [3]. Alitretinoin is licensed in Europe and Canada for oral treatment of severe 
chronic hand eczema refractory to potent topical steroids [4]. Up to now, there is only 
one case report by Molin and Ruzicka discussing the efficacy of oral alitretinoin in PRP 
[5]. 
Interestingly, a successful treatment with alitretinoin after multiple unsuccessful 
systemic therapies, including the administration of TNF-α antagonists, has never been 
reported so far. The present case report is intended to inspire additional studies and 
discussions with respect to the use of alitretinoin in adult-onset PRP type I. Such studies 
are definitely warranted by the encouraging reports. 
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Table 1. Details of previous treatments 
Generic name  Dose  Duration  Reason for stopping 
Acitretin  020 mg/day (p.o.)  02/2008–11/2009  no skin improvement 
Prednisone  010 mg/day (p.o.)  04/2008–02/2010  no skin improvement 
Bath PUVA  002–3 times/week  09/2008–12/2008  no skin improvement 
Cyclosporine  250 mg/day (p.o.)  12/2009–03/2010  worsening of arterial hypertension,  
no skin improvement 
Adalimumab  040 mg/2 weeks (s.c.)  01/2010–03/2010  relapse of PRP after initial skin 
improvement, elevation of liver enzymes
Methotrexate  015 mg/week (s.c.)  03/2010–04/2010  gastrointestinal side effects, diarrhea 
 
 
 
 
 
Fig. 1. Follicular papules and confluent erythematous scaly plaques with only rare ‘islands of sparing’. 
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Fig. 2. After 5 months of therapy with alitretinoin, the skin condition of our patient improved 
significantly with only slight residua of erythematous patches. 
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